Related Experiment Video
Updated: May 10, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection
Antonia Piazzesi1, Stefania Pane2, Federica Del Chierico1
1Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Insights
Children with COVID-19 have unique gut bacteria that may protect against severe disease. This study analyzed the gut microbiome and virome in pediatric patients, revealing protective microbial signatures and the impact of antibiotic treatments.
Area of Science:
- Microbiology
- Virology
- Immunology
Background:
- Children exhibit partial protection against SARS-CoV-2 infection and severe COVID-19.
- The gut microbiome's immunomodulatory role suggests it may influence pediatric COVID-19 outcomes.
- SARS-CoV-2 infects the gut, making the gut microbiota a potential factor in disease severity.
Purpose of the Study:
- To investigate the gut bacteriome and virome in pediatric COVID-19 patients.
- To identify microbial signatures associated with protection or severity in children.
- To assess the impact of antibiotic treatment on the pediatric gut microbiome and virome.
Main Methods:
- Shotgun metagenomic sequencing was employed to profile the gut bacteriome and virome.
- Pediatric patients with SARS-CoV-2 were compared to age-matched healthy controls.
- Analysis included the abundance of bacteria, viruses, bacteriophages, and antimicrobial resistance genes.
Main Results:
- Pediatric COVID-19 patients showed distinct protective bacterial signatures, unlike adult patients.
- Higher fecal Cytomegalovirus load was observed in COVID-19 patients.
- Antibiotic use altered the bacteriome, virome, and gene abundances (antimicrobial resistance, virulence).
Conclusions:
- The gut microbiome plays a significant role in pediatric COVID-19, with specific bacteria conferring protection.
- This is the first study to comprehensively analyze the bacteriome, virome, and resistome in pediatric COVID-19 patients and the effects of antibiotics.
Introduction:
Since the beginning of the SARS-CoV-2 pandemic in early 2020, it has been apparent that children were partially protected from both infection and the more severe forms of the disease. Many different mechanisms have been proposed to explain this phenomenon, including children's frequent exposure to other upper respiratory infections and vaccines, and which inflammatory cytokines they are more likely to produce in response to infection. Furthermore, given the presence of SARS-CoV-2 in the intestine and its ability to infect enterocytes, combined with the well described immunomodulatory capabilities of the microbiome, another potential contributing factor may be the presence of certain protective microbial members of the gut microbiota (GM).
Methods:
We performed shotgun metagenomic sequencing and profiled both the bacteriome and virome of the GM of pediatric SARS-CoV-2 patients compared to healthy, age-matched subjects.
Results:
We found that, while pediatric patients do share some pro-inflammatory microbial signatures with adult patients, they also possess a distinct microbial signature of protective bacteria previously found to be negatively correlated with SARS-CoV-2 infectivity and COVID-19 severity. COVID-19 was also associated with higher fecal Cytomegalovirus load, and with shifts in the relative abundances of bacteriophages in the GM. Furthermore, we address how the preventative treatment of COVID-19 patients with antibiotics, a common practice especially in the early days of the pandemic, affected the bacteriome and virome, as well as the abundances of antimicrobial resistance and virulence genes in these patients.
Discussion:
To our knowledge, this is the first study to address the bacteriome, virome, and resistome of pediatric patients in response to COVID-19 and to preventative antibiotics use.
More Related Videos
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
07:59Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 BSL-3 Conditions
Published on: September 10, 2021
Related Concept Videos
Development of Human Microbiota
Development of the Oral Microbiota
Microbiota of the Respiratory Tract
Microbiota of the Urogenital Tract
Human Virome
Bacterial Gastroenteritis